GEN-Y Biologics was formed in 2020 to license, productise and take to market superior antibody technologies derived from state-of-the-art technological platforms developed through their exclusive licensing partnership with the National University of Singapore’s highly prestigious Life Sciences Institute.
Their unique antibody discovery platform for fully human antibodies, together with advanced antibody engineering capabilities, provides a pipeline of highly specific antibodies for use in therapeutics and diagnostics.
Our technology employs a powerful method to screen human memory B cells from convalescent patients. Using a blend of bioinformatics, massive parallel sequencing and high throughput functional assays, we identify fully human monoclonal antibodies for research, therapy or diagnostics.
Our antibodies are expressed in high-yielding, industry standard mammalian expression platforms CHO and HEK
Blood sample taken at 3-5 days post-fever, for PCR and Dengue serotyping Day 60 post-fever sample collected for antibody screening
Recovered patient’s B Cells isolated from blood sample.
Each Memory B cell produces a single antibody.
Cells cultured in “pools” for several days with cytokines to stimulate antibody production.
Cells cultured in “pools” for several days with cytokines to stimulate antibody production.
Bioinformatics to identify individual antibody sequences
Multiplex Next Gen sequencing
mRNA isolated from positive B Cell pools and cDNA made.
Co-Founder, Chairman of the Board and Acting CFO
Co-Founder and Interim CEO
Co-Founder, Executive Director and CBO
Senior Scientific Advisor
Scientific Advisor
Scientific Advisor
Executive Director and Head of Commercial Operations
GEN-Y Biologics through the use of state-of-the-art technology and a unique antibody discovery platform discovers and develops fully human antibodies for use as therapies and diagnostics either alone or in collaboration with strategic partners.
GEN-Y Biologics through the use of state-of-the-art technology and a unique antibody discovery platform discovers and develops fully human antibodies for use as therapies and diagnostics either alone or in collaboration with strategic partners.